News | May 11, 2015

Boston Scientific Details Cardiology Growth and Expansion Plans to Investors

Presentation highlights include European launches for Watchman and Eluvia, expected FDA approval of Synergy bioabsorbable stent

Boston Scientific, investors, cardiology, growth, expansion

May 11, 2015 — Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth strategies at a meeting with the investment community May 1.

In the cardiovascular space, Boston Scientific continues to advance its drug-eluting stent portfolio with the ongoing clinical program for the Synergy everolimus-eluting bioabsorbable polymer platinum chromium coronary stent; U.S. Food and Drug Administration (FDA) approval is expected by year-end 2015. The company also announced the internal development of a fully resorbable stent platform.

New agreements with MedAxiom and TogetherMD are focused on improving clinical outcomes and lowering costs of delivering cardiovascular care through customized programs.

In the company's emerging structural heart business, next generations of the Watchman left atrial appendage closure platform and the Lotus Valve platform are planned to launch in Europe later this year.  

In peripheral intervention, the company is broadening its atherectomy and thrombectomy portfolio with its integration of the Bayer AG's Interventional business and a U.S. distribution agreement with C.R. Bard Inc. for the Lutonix drug coated balloon. Boston Scientific's Eluvia drug-eluting vascular stent system* is expected to launch in Europe in 2016 and enrollment continues in a novel clinical trial of its Vessix renal denervation system for patients with hypertension.

In cardiac rhythm management, the company focused on the soon-to-be-launched second-generation Emblem subcutaneous implantable defibrillator system (S-ICD). Boston Scientific presented plans for achieving magnetic resonance imaging (MRI) conditional-safe labeling across its pacemaker and ICD, S-ICD and cardiac resynchronization therapy defibrillator (CRT-D) platforms. Additionally, a leadless pacemaker development program will target the ability to pair with the Emblem S-ICD.

The company also plans to deliver next-generation ablation catheter platforms including an open irrigated version of IntellaTip MiFi and the IntellaNav family of navigation-enabled catheters. Both devices are expected to be built upon the foundation of technologies such as the EnduraLife battery technology and Rhythmia mapping system.

For more information:

Related Content

Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting | October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting | September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Overlay Init